Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Complex multifault rupture during the 2016 Mw 7.8 Kaikōura earthquake, New Zealand.

Hamling IJ, Hreinsdóttir S, Clark K, Elliott J, Liang C, Fielding E, Litchfield N, Villamor P, Wallace L, Wright TJ, D'Anastasio E, Bannister S, Burbidge D, Denys P, Gentle P, Howarth J, Mueller C, Palmer N, Pearson C, Power W, Barnes P, Barrell DJ, Van Dissen R, Langridge R, Little T, Nicol A, Pettinga J, Rowland J, Stirling M.

Science. 2017 Apr 14;356(6334). pii: eaam7194. doi: 10.1126/science.aam7194. Epub 2017 Mar 23.

2.

Chemotherapy port related lymphedema after axillary lymph node dissection.

Turfe Z, Pettinga J, Leduc O, Leduc A, Komorowska-Timek E.

Breast. 2016 Aug;28:145-7. doi: 10.1016/j.breast.2016.05.008. Epub 2016 Jun 16.

PMID:
27318169
3.

MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance.

Paulson AK, Linklater ES, Berghuis BD, App CA, Oostendorp LD, Paulson JE, Pettinga JE, Melnik MK, Vande Woude GF, Graveel CR.

Mol Cancer Res. 2013 Sep;11(9):1112-21. doi: 10.1158/1541-7786.MCR-13-0042. Epub 2013 Jul 3.

4.

Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer.

Hassett MJ, Silver SM, Hughes ME, Blayney DW, Edge SB, Herman JG, Hudis CA, Marcom PK, Pettinga JE, Share D, Theriault R, Wong YN, Vandergrift JL, Niland JC, Weeks JC.

J Clin Oncol. 2012 Jun 20;30(18):2218-26. doi: 10.1200/JCO.2011.38.5740. Epub 2012 May 14.

5.

Comparison of lymphedema in patients with axillary lymph node dissections to those with sentinel lymph node biopsy followed by immediate and delayed ALND.

Kuwajerwala NK, Feczko C, Dekhne N, Pettinga J, Lucia VC, Riutta J, Vicini F.

Am J Clin Oncol. 2013 Feb;36(1):20-3. doi: 10.1097/COC.0b013e31823a4956.

PMID:
22157215
6.

Improving breast cancer care through a regional quality collaborative.

Breslin TM, Caughran J, Pettinga J, Wesen C, Mehringer A, Yin H, Share D, Silver SM.

Surgery. 2011 Oct;150(4):635-42. doi: 10.1016/j.surg.2011.07.071.

PMID:
22000174
7.
9.

Changes in management techniques and patterns of disease recurrence over time in patients with breast carcinoma treated with breast-conserving therapy at a single institution.

Pass H, Vicini FA, Kestin LL, Goldstein NS, Decker D, Pettinga J, Ingold J, Benitez P, Neumann K, Rebner M, Dekhne N, Martinez A.

Cancer. 2004 Aug 15;101(4):713-20.

10.

Ongoing clinical experience utilizing 3D conformal external beam radiotherapy to deliver partial-breast irradiation in patients with early-stage breast cancer treated with breast-conserving therapy.

Vicini FA, Remouchamps V, Wallace M, Sharpe M, Fayad J, Tyburski L, Letts N, Kestin L, Edmundson G, Pettinga J, Goldstein NS, Wong J.

Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1247-53.

PMID:
14630258
11.

Estrogen replacement therapy in breast cancer survivors: a matched-controlled series.

Decker DA, Pettinga JE, VanderVelde N, Huang RR, Kestin L, Burdakin JH.

Menopause. 2003 Jul-Aug;10(4):277-85.

PMID:
12851510
12.

Giant mammary lipoma.

Lerman R, Pettinga J, Miller P, Amin MB, Pass HA.

Breast J. 2002 Sep-Oct;8(5):307-8. No abstract available.

PMID:
12199760
13.
14.

Mammographically detected ductal carcinoma in situ treated with conservative surgery with or without radiation therapy: patterns of failure and 10-year results.

Kestin LL, Goldstein NS, Martinez AA, Rebner M, Balasubramaniam M, Frazier RC, Register JT, Pettinga J, Vicini FA.

Ann Surg. 2000 Feb;231(2):235-45.

15.

Factors associated with local recurrence of mammographically detected ductal carcinoma in situ in patients given breast-conserving therapy.

Kestin LL, Goldstein NS, Lacerna MD, Balasubramaniam M, Martinez AA, Rebner M, Pettinga J, Frazier RC, Vicini FA.

Cancer. 2000 Feb 1;88(3):596-607.

PMID:
10649253
16.

Impact of young age on outcome in patients with ductal carcinoma-in-situ treated with breast-conserving therapy.

Vicini FA, Kestin LL, Goldstein NS, Chen PY, Pettinga J, Frazier RC, Martinez AA.

J Clin Oncol. 2000 Jan;18(2):296-306.

PMID:
10637243
17.

Impact of clinical, pathologic, and treatment-related factors on outcome in patients with locally advanced breast cancer treated with multimodality therapy.

Victor SJ, Horwitz EM, Kini VR, Martinez AA, Pettinga JE, Dmuchowski CF, Decker DA, Wilner FM, Vicini FA.

Am J Clin Oncol. 1999 Apr;22(2):119-25.

PMID:
10199443
18.

Treatment outcome with radiation therapy after breast augmentation or reconstruction in patients with primary breast carcinoma.

Victor SJ, Brown DM, Horwitz EM, Martinez AA, Kini VR, Pettinga JE, Shaheen KW, Benitez P, Chen PY, Vicini FA.

Cancer. 1998 Apr 1;82(7):1303-9.

PMID:
9529022
19.

Low-dose-rate brachytherapy as the sole radiation modality in the management of patients with early-stage breast cancer treated with breast-conserving therapy: preliminary results of a pilot trial.

Vicini FA, Chen PY, Fraile M, Gustafson GS, Edmundson GK, Jaffray DA, Benitez P, Pettinga J, Madrazo B, Ingold JA, Goldstein NS, Matter RC, Martinez AA.

Int J Radiat Oncol Biol Phys. 1997 May 1;38(2):301-10.

PMID:
9226316
20.

Outcome and prognostic factors for local recurrence in mammographically detected ductal carcinoma in situ of the breast treated with conservative surgery and radiation therapy.

White J, Levine A, Gustafson G, Wimbish K, Ingold J, Pettinga J, Matter R, Martinez A, Vicini F.

Int J Radiat Oncol Biol Phys. 1995 Feb 15;31(4):791-7.

PMID:
7860390
21.

Immunohistochemical analysis of P-glycoprotein expression in breast cancer: clinical correlations.

Decker DA, Morris LW, Levine AJ, Pettinga JE, Grudzien JL, Farkas DH.

Ann Clin Lab Sci. 1995 Jan-Feb;25(1):52-9.

PMID:
7762969

Supplemental Content

Loading ...
Support Center